Infringement of the Licensed Patents Sample Clauses

Infringement of the Licensed Patents. (a) Licensee will promptly inform [University] of any suspected infringement of a Licensed Patent by a third party.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Infringement of the Licensed Patents. 8.3.1 Each Party shall inform the other Parties promptly if it becomes aware (provided that in the case of UCLA, UCLA shall be deemed only to have become aware if the matter in question is in the awareness of the licensing officer responsible for administration of this Agreement) of:
Sample 1Sample 2
Infringement of the Licensed Patents. (a) If either Licensor or Licensee becomes aware of any infringement or potential infringement of Licensed Patents, each party shall promptly notify the other of such in writing.
Sample 1
Infringement of the Licensed Patents. 10.01 Rofin shall have a right to bring, maintain and settle patent infringement suits under the Licensed Patents against third parties. The costs and legal expenses of such a suit shall be borne by Rofin when Rofin brings the lawsuit. Boreal agrees to join any such lawsuit brought by Rofin at Rofin's expense. Boreal or Dr. John Tulip will assist and cooperate with Rofin in any such lawsuit, as requested by Rofin with Rofin to pay the reasonable expenses of Boreal or Dr. John Tulip incurred in connection with such assistance.
Sample 1
Infringement of the Licensed Patents. 13 ARTICLE XI DENTAL LASER SYSTEM JOINT DEVELOPMENT................................................13 ARTICLE XII OWNERSHIP OF LICENSED PATENTS, PROPRIETARY AND CONFIDENTIAL INFORMATION ............................................................14 ARTICLE XIII
Sample 1
Infringement of the Licensed Patents. 16.2.1. *** shall have the sole right, but after notifying ***, through counsel of its choosing, to take any measures it deems appropriate to stop infringement of the Licensed Patents for use pursuant to the License, by any Third Party or Sublicensee in the Territory or to grant to the infringing Third Party or Sublicensee adequate rights and licenses necessary for continuing such activities.
Sample 1
Infringement of the Licensed Patents. 6.2.1 Each Party shall inform the other Party promptly if it becomes aware of any infringement or potential infringement of any of the Licensed Patents, and the Parties shall consult with each other to decide the best way to respond to such infringement.
Sample 1
AutoNDA by SimpleDocs
Infringement of the Licensed Patents 
Sample 1

Related to Infringement of the Licensed Patents

  • Licensed Patents Subject to the terms and conditions of this Agreement, Marcas Modelo hereby grants, on behalf of itself and Grupo Modelo, to Constellation Beers an irrevocable, fully paid-up license or sub-license (as applicable) under the Licensed Patents (i) to make, have made (by Suppliers in accordance with this Agreement) and use Importer Products in the applicable Brewing Territory, and (ii) to sell (directly and/or indirectly), offer to sell, import and otherwise dispose of Interim Products and Importer Products in the Territory. The license rights granted in clause (i) of this Section 2.1(c) shall be non-exclusive and the license granted in clause (ii) of this Section 2.1(c) shall be exclusive solely in the Territory.

  • Patent Rights The State and the U. S. Department of Transportation shall have the royalty free, nonexclusive and irrevocable right to use and to authorize others to use any patents developed by the Engineer under this contract.

  • Joint Patents With respect to any potentially patentable Joint Invention, AstraZeneca shall have the first right, but not the obligation, to prepare patent applications based on such Joint Invention, to file and prosecute (including defense of any oppositions, interferences, reissue proceedings and reexaminations) such patent applications, and to maintain any Joint Patents issuing therefrom, in any jurisdictions throughout the Territory. FibroGen shall have the corresponding first right, but not the obligation, in any jurisdictions outside of the Territory other than China, in respect of which the China Agreement shall govern. If AstraZeneca determines in its sole discretion to abandon, cease prosecution or otherwise not file or maintain any Joint Patent anywhere in the Territory, then AstraZeneca shall provide FibroGen written notice of such determination at least thirty (30) days before any deadline for taking action to avoid abandonment (or other loss of rights) and shall provide FibroGen with the opportunity to prepare, file, prosecute and maintain such Joint Patent. The Party that is responsible for preparing, filing, prosecuting, and maintaining a particular Joint Patent (the “Prosecuting Party”) shall provide the other Party reasonable opportunity to review and comment on such prosecution efforts regarding such Joint Patent, and such other Party shall provide the Prosecuting Party reasonable assistance in such efforts. The Prosecuting Party shall provide the other Party with a copy of all material communications from any patent authority in the applicable jurisdictions regarding the Joint Patent being prosecuted by such Party, and shall provide drafts of any material filings or responses to be made to such patent authorities a reasonable amount of time in advance of submitting such filings or responses. In particular, each Party agrees to provide the other Party with all information necessary or desirable to enable the other Party to comply with the duty of candor/duty of disclosure requirements of any patent authority. Either Party may determine that it is no longer interested in supporting the continued prosecution or maintenance of a particular Joint Patent in a country or jurisdiction, in which case: (i) the disclaiming Party shall, if requested in writing by the other Party, assign its ownership interest in such Joint Patent in such country or jurisdiction to the other Party for no additional consideration; and (ii) if such assignment is effected, any such Joint Patent would thereafter be deemed a FibroGen Patent in the case of assignment to FibroGen, or a AstraZeneca Patent in the case of assignment to AstraZeneca; provided, however, that the disclaiming party would have an immunity from suit under such FibroGen Patent or AstraZeneca Patent, as the case may be, in the applicable country or jurisdiction. In addition, any Joint Patent that becomes a FibroGen Patent pursuant to the preceding sentence shall be excluded from the license granted to AstraZeneca in Section 7.1. Each Party shall bear its own internal costs in respect of the prosecution of Joint Patents. Out-of-pocket costs incurred in respect of the prosecution and maintenance of Joint Patents in the Territory shall be borne equally by AstraZeneca and FibroGen. In the event a Party elects to disclaim its interest in a Joint Patent, the costs incurred with respect to such Patent after the date of such disclaimer shall thereafter be borne exclusively by the other Party, without reimbursement or credit.

  • Infringement Controlled Affiliate shall promptly notify Plan and Plan shall promptly notify BCBSA of any suspected acts of infringement, unfair competition or passing off that may occur in relation to the Licensed Marks and Name. Controlled Affiliate shall not be entitled to require Plan or BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or passing off by third parties. Controlled Affiliate agrees to render to Plan and BCBSA, without charge, all reasonable assistance in connection with any matter pertaining to the protection of the Licensed Marks and Name by BCBSA.

  • Third Party Patents If any Third Party claims that a patent it owns or controls claims any aspect of a Licensed Product or its manufacture, use or sale, the Party with notice of such claim shall notify the other Party promptly, and the Parties shall as soon as practicable thereafter discuss in good faith regarding the best response.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!